ACTIVE_NOT_RECRUITING

Aldosterone Renin Ratio (ARR) Test to Increase Case-detection of Primary Aldosteronism (PA)

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The mission of this project is to increase the detection of Primary Aldosteronism (PA), the most common cause of secondary hypertension, which can either be cured surgically or treated with targeted medications.

Official Title

Aldosterone Renin Ratio (ARR) Test to Increase Case-detection of Primary Aldosteronism (PA)

Quick Facts

Study Start:2023-05-02

Study Completion:2025-12-29

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:ACTIVE_NOT_RECRUITING

Study ID

NCT05757076

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 65 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Not specified

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Consent to participate in the study * Participants limited to subjects in the CCF * Age between and inclusive of 18 and 65 years of age * No gender exclusion * Patients diagnosed with Essential Hypertension by ICD-10 code on at least two occasions in the previous six months, even if not on medications for hypertension * Patients on a single anti-hypertensive medication for at least six months with the diagnosis of hypertension	* Those on a mineralocorticoid antagonist therapy (spironolactone, eplerenone) * Those with a documented diagnosis of primary aldosteronism or primary hyperaldosteronism * Those with a diagnosis of secondary hyperaldosteronism * Those with a diagnosis of heart failure, renal artery stenosis, cirrhosis, ascites, cor pulmonale. * Pregnancy status (verbal)

Inclusion Criteria

Exclusion Criteria

* Consent to participate in the study
* Participants limited to subjects in the CCF
* Age between and inclusive of 18 and 65 years of age
* No gender exclusion
* Patients diagnosed with Essential Hypertension by ICD-10 code on at least two occasions in the previous six months, even if not on medications for hypertension
* Patients on a single anti-hypertensive medication for at least six months with the diagnosis of hypertension

* Those on a mineralocorticoid antagonist therapy (spironolactone, eplerenone)
* Those with a documented diagnosis of primary aldosteronism or primary hyperaldosteronism
* Those with a diagnosis of secondary hyperaldosteronism
* Those with a diagnosis of heart failure, renal artery stenosis, cirrhosis, ascites, cor pulmonale.
* Pregnancy status (verbal)

Contacts and Locations

Study Locations (Sites)

The Cleveland Clinic Foundation

Cleveland, Ohio, 44195

United States

Collaborators and Investigators

Sponsor: The Cleveland Clinic

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-05-02

Study Completion Date2025-12-29

Study Record Updates

Study Start Date2023-05-02

Study Completion Date2025-12-29

Terms related to this study

Additional Relevant MeSH Terms

Primary Aldosteronism